ALSTODT LANCE 4
4 · BioRestorative Therapies, Inc. · Filed Jan 24, 2023
Insider Transaction Report
Form 4
ALSTODT LANCE
DirectorPresident, CEO, COB
Transactions
- Purchase
Common Stock
2023-01-20$3.10/sh+100$310→ 186,621 total - Purchase
Common Stock
2023-01-20$3.17/sh+100$317→ 186,721 total
Holdings
- 293,479
Stock Option
Exercise: $5.08Exp: 2031-03-18→ Common Stock (293,479 underlying) - 42,059
Stock Option
Exercise: $5.08Exp: 2031-11-04→ Common Stock (42,059 underlying)
Footnotes (3)
- [F1]Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
- [F2]The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
- [F3]The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.